Where Genmab Stands With Analysts
Portfolio Pulse from Benzinga Insights
Genmab (NASDAQ:GMAB) has received 6 bullish and 3 somewhat bearish ratings in the last quarter. The average 12-month price target for the stock has increased by 4.76% to $44.0, with a high of $51.00 and a low of $33.00.
June 26, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Genmab has received a mix of bullish and somewhat bearish ratings in the last quarter, with an average 12-month price target of $44.0.
The mixed analyst ratings for Genmab indicate that there is no clear consensus on the stock's short-term price direction. The average 12-month price target of $44.0 suggests a potential upside, but the presence of somewhat bearish ratings also implies caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100